Home » Posts tagged with » California
Ligand Pharmaceuticals to acquire protein therapeutics developer Pfenex

Ligand Pharmaceuticals to acquire protein therapeutics developer Pfenex

US biopharma company Ligand Pharmaceuticals has signed a deal worth up to $516 million to acquire Pfenex, a development and licensing biotechnology company engaged in the development of protein therapeutics, which are used in various commercial and development-stage biopharma drug candidates. As per the terms of the deal, Ligand Pharmaceuticals is offering to acquire the […]

Siemens Healthineers to acquire cancer care technologies developer Varian Medical Systems

Siemens Healthineers acquisition of Varian Medical Systems : Germany-based Siemens Healthineers has signed an all-cash deal worth around $16.4 billion to acquire US-based cancer care technologies developer Varian Medical Systems with an objective to strengthen its oncology portfolio and bolster its position in the healthcare sector. Based in California, Varian Medical Systems is among the […]

Continue reading …
Tenzing to acquire clinical-stage pharma company Reviva Pharmaceuticals

Tenzing Acquisition has agreed to acquire Reviva Pharmaceuticals, a California-based clinical-stage pharma company, focused on developing therapies for addressing unmet medical needs in the areas of central nervous system, metabolic, cardiovascular, and inflammatory diseases. According to the British Virgin Islands-incorporated special purpose acquisition company, the equity value of the combined company post its merger with […]

Continue reading …
KSI-301 phase 1b trial : Kodiak Sciences reports new safety, efficacy, and durability data

KSI-301 phase 1b trial : Kodiak Sciences said that its ongoing phase 1b clinical trial of its intravitreal anti-VEGF antibody biopolymer conjugate KSI-301 for the treatment of patients with treatment-naïve wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO), has yielded promising additional safety, efficacy and durability data. According […]

Continue reading …
BrainStorm Cell Therapeutics doses patients in NurOwn phase 3 trial in ALS

NurOwn phase 3 trial : BrainStorm Cell Therapeutics, a US biotech company engaged in developing adult stem cell therapies for neurodegenerative diseases, has completed the dosing of all the participants in a phase 3 trial of NurOwn (MSC-NTF cells) in amyotrophic lateral sclerosis (ALS). The late-stage trial enrolled nearly 200 participants, who have been randomized […]

Continue reading …
Gilead to acquire stake in cancer immunotherapy company Pionyr Immunotherapeutics

Gilead Sciences has agreed to acquire a stake of 49.9% in California-based cancer immunotherapy company Pionyr Immunotherapeutics, for $275 million. The pharma major has also secured an exclusive option to acquire the remaining stake in Pionyr Immunotherapeutics. As per the agreement, shareholders of the cancer immunotherapy company could be paid an additional $1.47 billion in […]

Continue reading …
Polycythemia vera treatment : Protagonist Therapeutics’ PTG-300 gets FDA ODD

Protagonist Therapeutics has bagged the orphan drug designation (ODD) from the US Food and Drug Administration (FDA) for PTG-300 for polycythemia vera treatment. Polycythemia vera is a type of blood cancer, which is mainly characterized by the increased production of red blood cells. According to the California-based biopharma company, PTG-300 is an injectable synthetic peptide […]

Continue reading …
Gene therapy company 4D Molecular Therapeutics raises $70m in Series C round

California-based gene therapy company 4D Molecular Therapeutics (4DMT), which is focused on adeno-associated virus (AAV) gene therapy vector discovery and product development, has raised $70 million through a Series C financing round. The Series C financing round was led by Viking Global Investors. It also saw participation from new investors such as Amzak Health, Casdin […]

Continue reading …
Sorrento Therapeutics says STI-1499 fully inhibited SARS-CoV-2 virus

Sorrento Therapeutics said that STI-1499, its anti-SARS-CoV-2 antibody, showed 100% inhibition of SARS-CoV-2 virus infection in an in vitro virus infection experiment at a very low antibody concentration. The US biotech company will look to create an antibody cocktail product that will work as a protective shield against SARS-CoV-2 coronavirus infection and stay effective even […]

Continue reading …
Eiger BioPharmaceuticals doses first patients with Lambda in COVID-19 trial

Eiger BioPharmaceuticals said that it has dosed the first patients in a phase 2 trial of its hepatitis delta virus drug candidate peginterferon lambda (Lambda) in outpatients at the Stanford University School of Medicine having mild COVID-19. The California-based biopharma company said that nearly 120 patients will be randomly grouped in a 1:1 ratio to […]

Continue reading …
Page 1 of 6123Next ›Last »